30-Second Takeaway
- 2026 EAU male LUTS guideline tightens diagnostic workup and treatment across age groups, including new guidance for younger men.
- Perioperative tranexamic acid lowers major bleeding in urologic surgery without a clear thrombotic signal.
- Real-world NMIBC surveillance is misaligned with risk, overusing cystoscopy in low-risk and underusing it in high-risk disease.
Week ending April 25, 2026
Practice-shaping updates in male LUTS, perioperative bleeding control, bladder cancer surveillance, and precision prostate cancer care
2026 EAU guideline overhaul for non-neurogenic male LUTS
The 2026 EAU guideline for non-neurogenic male LUTS updates diagnostic, conservative, and surgical recommendations using a structured evidence review to 2025. Systematic reviews, randomized trials, and prospective comparative studies inform revisions across all chapters, including benign prostatic obstruction management. A new section on voiding dysfunction in young men acknowledges distinct etiologies and tailored evaluation and treatment needs in this group. The guideline aims to standardize evidence-based care and reduce practice variation in male LUTS management.
Tranexamic acid cuts major bleeding in urologic surgery in POISE-3
In 1124 urologic surgery patients, tranexamic acid reduced major bleeding versus placebo (6.1% vs 9.5%; HR 0.63, 95% CI 0.41-0.97). The broader 30-day composite bleeding outcome also favored tranexamic acid, though with less precise estimates (HR 0.73, 95% CI 0.50-1.07). Thirty-day thrombotic events, including MINS, stroke, and symptomatic proximal VTE, were similar between groups (HR 1.12, 95% CI 0.79-1.58). Effects did not differ by surgical approach, cancer status, or recent antithrombotic use, supporting TXA use in high-bleeding-risk cases without prohibitive thrombosis risk.
NMIBC surveillance frequently diverges from guideline intensity by risk group
This Dutch population-based analysis of 2791 NMIBC tumors compared cystoscopy surveillance with guideline recommendations by risk category. Over one-third of low-risk patients were monitored more intensively than recommended, despite a mean of only 1.3 cystoscopies in year one. Intermediate-risk surveillance was initially guideline-concordant, but undertreatment rose over time, with under-surveillance increasing from 21.7% to 39.8%. Most high-risk tumors (88.2%) were monitored less than recommended, although adherence improved somewhat over time. Cytology, imaging, and biopsies were widely used, yet symptoms did not meaningfully alter surveillance intensity, highlighting opportunities to re-align follow-up with risk.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.